Navigation Links
Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
Date:2/7/2008

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that data from the Phase II trial of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronary heart disease will be presented as a late breaker at the 2008 American College of Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 in Chicago, Illinois.

The Phase II trial known as PLASMA (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was a reduction in secretory phospholipase A2 (sPLA2). The study also evaluated the effect of Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as well as inflammation in patients with stable coronary heart disease.

PLASMA Late-Breaker Trial Data Presentation:

Date/Time: Monday, March 31 from 2:30-2:45pm.

Title/Author: Effects of a Selective Inhibitor of Secretory

Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways,

Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical

Atherosclerosis Research, Division of Cardiovascular Medicine at the

University of Michigan, for the PLASMA Investigators.

Location: McCormick Place, Vista Room S406

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co. Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com.

MEDIA CONTACT:

Anne Bowdidge (650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology: